Tickers

1. Composite Trajectory Verdict

For a specialty E&S insurer, underwriting profitability (income statement), reserve adequacy and capital position (balance sheet), and operating cash generation (cash flow) are all core to financial performance and carry roughly equal weight.

Composite Trajectory: Improving

The annual trend across all three statements is consistently positive: net income grew 21.4% in 2025 over 2024 and 34.6% in 2024 over 2023; operating cash flow rose each year to $1.04B in 2025; and stockholders' equity expanded 32% to $1.96B while debt-to-equity fell to 11.4%. The combined ratio improved to 75.9% in 2025 from 76.4% in 2024, driven by favorable prior-year reserve development of $62.8M. The most recent quarter (Q2 2026) shows continued earnings growth (+31% YoY) and a lower combined ratio (75.5% vs 75.8%), though gross written premiums declined 5% and the expense ratio rose to 21.7% from 20.7%. No statement shows deterioration; the quarterly premium deceleration is offset by stronger underwriting margins and investment results.

2. Red Flags

• Commercial Property gross written premiums fell 17.9% in FY2025 (10-K 2025, MD&A) and 32.7% in Q2 2026 (10-Q Q2 2026, MD&A), the largest division by premium volume.
• Expense ratio increased annually from 20.6% to 20.8% (10-K 2025, MD&A) and quarterly from 20.7% to 21.7% (10-Q Q2 2026, MD&A), attributed to lower ceding commissions from higher reinsurance retention.
• Net retention ratio rose to 81.7% in 2025 from 79.0% in 2024 (10-K 2025, MD&A), increasing net exposure to catastrophe and large losses.
• Adverse prior-year development persists in construction liability (2016-2019 accident years) and from inflation uncertainty on construction defect exposures (10-K 2025, MD&A; Note 7).
• A $140M jury verdict against a policyholder (Venetian Hills) was vacated and ordered for retrial; the Company believes policy exclusions apply but resolution may take years (10-K 2025, Note 12).
• Return on equity declined to 29.3% from 32.3% and operating ROE to 26.4% from 29.2% (10-K 2025, MD&A) due to equity growth outpacing earnings.
• Share repurchases accelerated to $90M in 2025 from $10M in 2024 (10-K 2025, Cash Flows), while a new $250M program was authorized in December 2025.

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Overall Assessment: Net income rose to $503.6M in FY2025 from $414.8M in FY2024 (+21.4%) and $308.1M in FY2023 (+34.6% YoY in 2024) (10-K 2025, Consolidated Statements of Operations). Underwriting income (non-GAAP) increased to $389.2M from $325.9M (+19.4%) (10-K 2025, MD&A). The combined ratio improved to 75.9% from 76.4%, with the loss ratio falling to 55.1% from 55.8% due to higher favorable prior-year development ($62.8M vs $37.7M) (10-K 2025, MD&A). Net earned premiums grew 16.7% to $1.58B (10-K 2025, Consolidated Statements of Operations). In Q2 2026, net income rose 31.1% to $175.9M vs $134.1M in Q2 2025, with combined ratio improving to 75.5% from 75.8%, though gross written premiums fell 5.0% and the expense ratio increased to 21.7% from 20.7% (10-Q Q2 2026, MD&A). Fee income and net investment income grew consistently in both annual and quarterly comparisons.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Overall Assessment: Net cash from operating activities increased each year: $859.8M (2023), $976.3M (2024), $1,043.7M (2025) (10-K 2025, Consolidated Statements of Cash Flows). The growth reflects higher premium collections and timing of claim payments and reinsurance recoveries (10-K 2025, MD&A). Investing cash outflows were stable at ~$920-960M annually, funding fixed-maturity purchases of $2.5B in 2025 vs $1.6B in 2024 (10-K 2025, MD&A). Financing outflows rose to $71.4M in 2025 from $29.7M in 2024, driven by $90M of share repurchases vs $10M and a $40M credit facility draw for headquarters construction (10-K 2025, Consolidated Statements of Cash Flows). Quarterly cash flow statements are not provided in the 10-Q excerpts.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Overall Assessment: Total assets grew to $6.04B at 12/31/2025 from $4.89B at 12/31/2024 (+23.7%) (10-K 2025, Consolidated Balance Sheets). Stockholders' equity rose 32.1% to $1.96B from $1.48B, driven by retained earnings ($1.72B vs $1.23B) and accumulated other comprehensive income improvement (-$30.7M vs -$97.2M) (10-K 2025, Consolidated Balance Sheets). Total debt increased modestly to $224.4M from $184.1M, but debt-to-equity fell to 11.4% from 12.4% (10-K 2025, Note 11). Gross loss reserves grew to $2.89B from $2.29B (+26.4%), with net reserves at $2.51B vs $1.96B; 91.2% of net reserves are IBNR (10-K 2025, Critical Accounting Estimates). Favorable prior-year development of $62.8M in 2025 and $37.7M in 2024 supports reserve adequacy (10-K 2025, Note 7). Statutory capital and surplus at the insurance subsidiary rose to $1.93B from $1.53B (10-K 2025, Note 16). Investment portfolio quality remains high: 81.9% rated A- or better (10-K 2025, Note 2).

6. Data Gaps

• Quarterly cash flow statements for Q1 2026, Q2 2026, Q3 2025 (not included in 10-Q excerpts)
• Full Q1 2026 income statement and MD&A (10-Q 2026-03-31 text truncated in provided filings)
• Q3 2025 and Q4 2025 quarterly results (only annual FY2025 in 10-K; 10-Q 2025-09-30 not fully provided)
• 2023 combined ratio, loss ratio, and expense ratio (not explicitly stated in 10-K summary tables)
• Quarterly balance sheets for 2026 periods
• Detailed breakdown of "Other segment items" in underwriting expenses for quarterly periods
• Reinsurance treaty terms beyond the catastrophe program description (attachment points, quota share percentages)